These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 33548518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ, Gyllfors P, Valovirta E, Steffensen MA, Grønager PM, Savolainen J, Winther L.
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [Abstract] [Full Text] [Related]

  • 3. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Biedermann T, Kuna P, Panzner P, Valovirta E, Andersson M, de Blay F, Thrane D, Jacobsen SH, Stage BS, Winther L.
    J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK, Tenn MW, Steacy LM, Adams DE, Day AG, Walker TJ, Nolte H.
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J.
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
    Nelson HS, Bernstein DI, Biedermann T, Nolte H.
    Allergy Asthma Proc; 2024 Jan 01; 45(1):33-36. PubMed ID: 38151733
    [Abstract] [Full Text] [Related]

  • 14. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ.
    J Allergy Clin Immunol; 2011 Sep 01; 128(3):559-66. PubMed ID: 21802126
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis.
    Devillier P, Dreyfus JF, Demoly P, Calderón MA.
    BMC Med; 2014 May 01; 12():71. PubMed ID: 24885894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons.
    Yang J, Wang W, Shen Z, Kang W, Zhang P, Chen X, Li H, Shao Y, Liu L, Zhang S, Quan F.
    Eur Arch Otorhinolaryngol; 2023 Nov 01; 280(11):4939-4947. PubMed ID: 37365351
    [Abstract] [Full Text] [Related]

  • 19. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.
    Clin Ther; 2011 Jul 01; 33(7):828-40. PubMed ID: 21741092
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Reymond C.
    J Allergy Clin Immunol; 2016 Jul 01; 138(1):162-8. PubMed ID: 27373329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.